Publicaciones en colaboración con investigadores/as de National and Kapodistrian University of Athens (196)

2024

  1. Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study

    United European Gastroenterology Journal

  2. Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX

    Blood Advances, Vol. 8, Núm. 2, pp. 388-398

  3. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

    eClinicalMedicine, Vol. 71

  4. Dietary intake of vitamin C and gastric cancer: a pooled analysis within the Stomach cancer Pooling (StoP) Project

    Gastric Cancer, Vol. 27, Núm. 3, pp. 461-472

  5. Endovascular Thrombectomy Treatment Effect in Direct vs Transferred Patients with Large Ischemic Strokes: A Prespecified Analysis of the SELECT2 Trial

    JAMA Neurology, Vol. 81, Núm. 4, pp. 327-335

  6. Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trial

    European Journal of Haematology

  7. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216

  8. Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine

    The Lancet Respiratory Medicine, Vol. 12, Núm. 4, pp. 305-322

  9. Reproductive factors, hormonal interventions, and gastric cancer risk in the Stomach cancer Pooling (StoP) Project

    Cancer Causes and Control, Vol. 35, Núm. 4, pp. 727-737

  10. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

    Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152

  11. Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 2, pp. e40-e49.e3

2023

  1. Adult height and risk of gastric cancer: A pooled analysis within the Stomach cancer Pooling Project

    European Journal of Cancer Prevention, Vol. 32, Núm. 3, pp. 215-221

  2. Association of Endovascular Thrombectomy vs Medical Management with Functional and Safety Outcomes in Patients Treated beyond 24 Hours of Last Known Well: The SELECT Late Study

    JAMA Neurology, Vol. 80, Núm. 2, pp. 172-182

  3. Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 9, pp. 687-696

  4. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 14, pp. 2607-2616

  5. Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia

    Leukemia, Vol. 37, Núm. 2, pp. 388-395

  6. Differences in the immunoglobulin gene repertoires of IgG versus IgA multiple myeloma allude to distinct immunopathogenetic trajectories

    Frontiers in Oncology, Vol. 13

  7. Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study

    Blood Advances, Vol. 7, Núm. 14, pp. 3739-3748

  8. Liver investigation: Testing marker utility in steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol

    Contemporary Clinical Trials, Vol. 134

  9. MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials

    Blood, Vol. 141, Núm. 6, pp. 579-591